No Data
Trending Industry Today: CARSGEN-B Leads Gains In Pharmaceutical Companies Stocks
EVEREST MED-B (01952.HK) plans to hold a Board of Directors meeting on March 25 to approve the annual performance.
Gelonghui reports on February 25 that EVEREST MED-B (01952.HK) announced that the Board of Directors will hold a board meeting on March 25, 2025 (Tuesday) to consider and approve the group's annual performance for the year ending December 31, 2024, as well as to address Other matters.
EVEREST MED-B: DATE OF BOARD MEETING
Goldman Sachs released a deep investment value report on Biomedical in China, raising the Target Price for Cloudtop New Horizon (01952) to 48.32 Hong Kong dollars.
Goldman Sachs released a comprehensive analysis report on the investment value of biotechnology in China's Medical Care sector, suggesting that China's position as a source of innovation is increasingly prominent and will gain broader recognition globally. In the report, the Hong Kong-listed innovative drug company, Yun Tian Xin Yao (01952), received significant attention.
[Brokerage Focus] BOCOM INTL points to new opportunities in the medical Sector driven by AI technology, focusing on innovation related to AI and opportunities for valuation recovery.
Jingu Finance News | BOCOM INTL stated that multiple pharmaceutical companies have integrated DeepSeek, accelerating the implementation of AI + Medical Services. Many companies in the digital medical field, such as Yidu Technology, announced the integration of DeepSeek-R1 model, and Jiangsu Hengrui Pharmaceuticals and INNOVENT BIO also indicated that they will fully carry out DeepSeek application work. Moreover, the National Healthcare Security Administration has reiterated the reform of payment collection. The administration mentioned the achievements of the settlement reform in Jiangxi Province, where the payment collection cycle for medical supply companies has reduced from half a year to 30 days. The bank pointed out that AI large models empower digital medical services companies, showing significant potential in disease diagnosis/detection. At the same time,
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
